Eli Lilly and Company and Incyte Corporation announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis. Baricitinib is a once daily, oral, selective JAK1 and JAK2 inhibitor.
The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional disease-modifying antirheumatic drug (cDMARD). Patients received either one of two doses of once-daily baricitinib or placebo, in addition to their background therapy. The study met its primary endpoint of an improved ACR20 response rate compared to placebo after 12 weeks of treatment.
Baricitinib is currently in Phase 3 clinical development for rheumatoid arthritis and Phase 2 development for psoriasis and diabetic nephropathy.